Clinical Aspects of Drug-Drug Interaction and Drug Nephrotoxicity at Renal Organic Cation Transporters 2 (OCT2) and Multidrug and Toxin Exclusion 1, and 2-K (MATE1/MATE2-K)

被引:0
|
作者
Saad, Abdulaziz Ahmed A. [1 ]
Zhang, Fan [2 ]
Mohammed, Eyad Abdulwhab H. [1 ]
Wu, Xin'an [2 ]
机构
[1] Lanzhou Univ, Sch Pharm, Lanzhou 730000, Peoples R China
[2] Lanzhou Univ, Hosp 1, Dept Pharm, Lanzhou 730000, Peoples R China
关键词
drug-drug interaction; nephrotoxicity; organic cation transporter 2; multidrug and toxin extrusion 1 and 2-K; CISPLATIN-INDUCED NEPHROTOXICITY; SOLUTE CARRIER TRANSPORTERS; EXTRUSION PROTEINS; KIDNEY INJURY; TARGETED DISRUPTION; GENETIC-VARIANTS; METFORMIN; MATE1; CIMETIDINE; PHARMACOKINETICS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The organic cation transporter 2 (OCT2) belongs to the SLC22 family, while the multidrug and toxin extrusion 1 and 2-K (1VIATE1/MATE2-K) belong to the SLC47 family, are localized to the basolateral and apical membrane of human renal proximal tubular epithelial cells, respectively. They are polyspecific transporters that enable the transit of structurally diversified drugs with overlapping selectivity across plasma membranes. OCT2 and MATE1/2-K are critically involved in renal secretion, pharmacokinetics (PK), and toxicity of cationic drugs. Drug-drug interactions (DDIs) at OCT2 and/or MATEI/2-K have been shown to result in clinical impacts on PK, therapeutic efficacy and are probably involved in the renal accumulation of drugs. Sites of OCT2 and MATE1/2-K expression and function play an essential role in the pharmacokinetics and toxicity of drugs, such as cisplatin. Thus, knowing the sites (basolateral vs. apical) of the interaction of two drugs at transporters is essential to understanding whether this interaction helps prevent or enhance drug-induced nephrotoxicity. In this work, an overview of OCT2 and MATE1/2-K is presented. Primary structure, membrane location, functional properties, and clinical impact of OCT2 and MATE1/2-K are presented. In addition, clinical aspects of DDIs in OCT2 and MATE1/2-K and their involvement in drug nephrotoxicity are compiled.
引用
收藏
页码:382 / 393
页数:12
相关论文
共 50 条
  • [41] Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters
    Reznicek, Josef
    Ceckova, Martina
    Cerveny, Lukas
    Mueller, Fabian
    Staud, Frantisek
    XENOBIOTICA, 2017, 47 (01) : 77 - 85
  • [42] Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein
    Knop, Jana
    Misaka, Shingen
    Singer, Katrin
    Hoier, Eva
    Mueller, Fabian
    Glaeser, Hartmut
    Koenig, Joerg
    Fromm, Martin F.
    PLOS ONE, 2015, 10 (10):
  • [43] Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects
    Trivedi, Ashit
    Oberoi, Rajneet K.
    Jafarinasabian, Pegah
    Zhang, Hanze
    Spring, Marintan
    Flach, Stephen
    Abbasi, Siddique
    Dutta, Sandeep
    Lee, Edward
    CLINICAL DRUG INVESTIGATION, 2021, 41 (07) : 647 - 652
  • [44] FUNCTIONAL EVALUATION OF AMINO ACID VARIANTS OF SLC47A FAMILY (MATE1 AND MATE2-K)
    Kajiwara, Moto
    Terada, Tomohiro
    Ogasawara, Ken
    Iwano, Junko
    Katsura, Toshiya
    Inui, Ken-ichi
    JOURNAL OF PHYSIOLOGICAL SCIENCES, 2009, 59 : 435 - 435
  • [45] Effect of Omecamtiv Mecarbil on the Pharmacokinetics of Metformin, a Probe Substrate for MATE1/MATE2-K, in Healthy Subjects
    Ashit Trivedi
    Rajneet K. Oberoi
    Pegah Jafarinasabian
    Hanze Zhang
    Marintan Spring
    Stephen Flach
    Siddique Abbasi
    Sandeep Dutta
    Edward Lee
    Clinical Drug Investigation, 2021, 41 : 647 - 652
  • [46] USE OF A RENAL OCT2/MATE BIOMARKER (N1-METHYLNICOTINAMIDE) TO ENABLE THE EARLY CLINICAL ASSESSMENT OF METFORMIN DRUG INTERACTION POTENTIAL
    Mathialagan, Sumathy
    Rodrigues, A. David
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 55
  • [47] NEPHROTOXICITY IN MATE1, MATE2K AND MATE1/2K KNOCKOUT CELL LINES FOLLOWING TREATMENT WITH CISPLATIN USING THE MIMETAS 3D ORGANOPLATE PLATFORM
    Steiner, Toni
    Thompson, David
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S97 - S98
  • [48] Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2
    Shu, Wenying
    Ma, Lei
    Hu, Xiaoye
    Zhang, Meimei
    Chen, Wensheng
    Ma, Wen
    Huang, Jianing
    Li, Jia
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 142
  • [49] The OCT2/MATE1 Interaction Between Trifluridine, Metformin and Cimetidine: A Crossover Pharmacokinetic Study
    Guchelaar, Niels A. D.
    Buck, Stefan A. J.
    van Doorn, Leni
    Hussaarts, Koen G. A. M.
    Sandberg, Yorick
    van der Padt-pruijsten, Annemieke
    van Alphen, Robbert J.
    Poppe-Manenschijn, Laura
    Vleut, Isolde
    de Bruijn, Peter
    van Leeuwen, Roelof W. F.
    Mostert, Bianca
    Eskens, Ferry A. L. M.
    Oomen-de Hoop, Esther
    Koolen, Stijn L. W.
    Mathijssen, Ron H. J.
    CLINICAL PHARMACOKINETICS, 2024, 63 (07) : 1037 - 1044
  • [50] Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations
    Koenig, J.
    Zolk, O.
    Singer, K.
    Hoffmann, C.
    Fromm, M. F.
    BRITISH JOURNAL OF PHARMACOLOGY, 2011, 163 (03) : 546 - 555